Sera Prognostics is Named a 2017 Silver Edison Award Winner
PreTRM® Test Wins at New York Ceremony; Awards Celebrate 30 Years of Honoring Innovators and Innovation
NEW YORK, April 21, 2017 (GLOBE NEWSWIRE) -- Read more...
Research on Fetal Sex Differences in Predicting Spontaneous Preterm Birth Using Sera’s Proteomic Technology to be Presented at The 64th Annual Society for Reproductive Investigation Meeting
SALT LAKE CITY, March 13, 2017 (GLOBE NEWSWIRE) -- Sera Prognostics, Inc., a women’s healthcare company, today announced that research using Sera’s Read more...
Phase 3 Trial Data Show Use of SpaceOAR® Hydrogel Helps Maintain Erectile Function Following Prostate Cancer Radiation Treatment
Lower penile bulb radiation dose may be associated with ability to maintain sexual function and potency
BEDFORD, Mass.--(BUSINESS WIRE)--Augmenix, Read more...
Sera Prognostics’ PreTRM® Named Edison Awards Finalist
PreTRM® to be Recognized at Edison Awards Gala on April 20, 2017 in New York
SALT LAKE CITY, Feb. 09, 2017 (GLOBE NEWSWIRE) -- Sera Prognostics, a women’s Read more...
SERA PROGNOSTICS ENTERS INTO AGREEMENT WITH LABCORP TO BE THE EXCLUSIVE U.S. DISTRIBUTOR OF PRETRM® TEST
SALT LAKE CITY, January 10, 2017– LabCorp Leads $40 Million Series C Financing as Sera Expands its Activities to Address Premature Birth
Sera Prognostics, Read more...
Augmenix To Present at the 35th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass.--(BUSINESS WIRE)--Augmenix, Inc. a medical technology company that develops, manufactures, and sells proprietary absorbable hydrogels that Read more...
Augmenix Announces New Category 1 CPT® Code from the American Medical Association for Periprostatic Implantation of Biodegradable Material
The CPT Code establishes a standard reimbursement pathway for this new procedure which is performed with SpaceOAR®technology
WALTHAM, Mass.--(BUSINESS Read more...
SMART MONEY IN MED TECH: WHAT IT MEANS AND WHY IT MATTERS
August 22, 2016
by Amy Siegel
As the route to a successful exit in med tech has grown longer, and the pathway riskier and more expensive, many VCs Read more...
